MedTrace Logo

Evaluating Novel Biomarkers in Acute Kidney Injury

NCT01573104 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2015-05-27

No results posted yet for this study

Summary

The investigators have a new technique of looking at urine to see whether it contains protein fragments that are released by damaged kidneys. These fragments seem to be more accurate than the current blood tests that the investigators use to diagnose renal failure. This technique needs to be validated with a group of patients that have a relatively high incidence of renal failure, cardiopulmonary bypass.

The investigators hypothesise that using novel markers of renal dysfunction will identify patients who go on to develop renal failure earlier, and in a higher number than the standard blood tests.

The investigators aim to collect urine from patients before going onto bypass, and then at Day 1 and Day 2 after bypass. This urine will be analysed for protein fragments, as well as other new markers of renal dysfunction. The investigators will also take blood at baseline and for the first two days in Cardiac Intensive Care, and compare the accuracy of the new tests with the 'gold standard' that is creatinine.

Conditions

Interventions

OTHER

Proteomic assay

Urine will be taken for proteomic assay at baseline, day 1 and day 2

OTHER

Blood sampling

Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2

OTHER

Biomarker sampling

Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date

Sponsors & Collaborators

  • Dr Robert Docking

    lead OTHER

Principal Investigators

  • John Kinsella, MD, FRCA · University of Glasgow

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-01-31
Completion
2015-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01573104 on ClinicalTrials.gov